Market Exclusivity Decision Pending For Bayer’s First-In-Class OTC Switch Astepro Allergy

 
• By Malcolm Spicer
  
Astepro Allergy labeling was approved with Bayer's NDA for an OTC switch of azelastine hydrochloride nasal spray. • Source: FDA
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Rx-to-OTC Switch

More from Health